Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $78.00 | Overweight | Barclays |
| 6/4/2025 | $38.00 | Neutral → Buy | H.C. Wainwright |
| 2/4/2025 | $25.00 | Outperform | Wolfe Research |
| 12/11/2024 | $52.00 → $19.00 | Buy → Neutral | H.C. Wainwright |
| 12/2/2024 | Buy → Neutral | BTIG Research | |
| 7/22/2024 | $55.00 | Buy | H.C. Wainwright |
| 7/19/2024 | $29.00 → $69.00 | Neutral → Overweight | JP Morgan |
| 4/16/2024 | $47.00 | Outperform | Leerink Partners |
10-Q - ANAPTYSBIO, INC (0001370053) (Filer)
8-K - ANAPTYSBIO, INC (0001370053) (Filer)
8-K - ANAPTYSBIO, INC (0001370053) (Filer)
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025Phase 2b data for rosnilimab in rheumatoid arthritis featured as late-breaking oral presentation at ACR Convergence 2025Phase 1b initiated in celiac disease for ANB033, a CD122 antagonist; top-line Phase 1b data anticipated in Q4 2026GSK announced strong commercial performance for Jemperli, growing >16% quarter-over-quarter to $303 million in Q3 2025 and $785 million YTD 2025Anaptys anticipates accruing a one-time $75 million commercial sales milestone in Q4 2025 from GS
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen Immunology & Inflammation Summit, Virtual Format – Fireside chatDate and Time – Wednesday, Nov. 12, 2025 at 8:00am ET Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA Format – Fireside chat and 1x1 investor meetingsDate and Time – Wednesday, Nov. 12, 2025 at 11:30am ET Stifel 2025
New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKsNew data confirm durable clinical benefit across multiple higher-order response measures, including CDAI LDA and DAS28 LDA, after Week 28 for at least three months off drugUpdated safety data through Week 38 demonstrate rosnilimab was well-tolerated with no treatment-related serious adverse events and no malignancies in rosnilimab-treated patients SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on de
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
Barclays initiated coverage of AnaptysBio with a rating of Overweight and set a new price target of $78.00
H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00
Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00
SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.
After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a
Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b